Clinical Trials in Stargardt Disease Treatment
Springer International Publishing (Verlag)
978-3-031-58806-8 (ISBN)
- Noch nicht erschienen - erscheint am 27.07.2024
- Versandkostenfrei innerhalb Deutschlands
- Auch auf Rechnung
- Verfügbarkeit in der Filiale vor Ort prüfen
- Artikel merken
This book is a compendium of the worldwide ocular stem cell, gene therapy, pharmaceutical, and other miscellaneous studies treating Stargardt Disease registered with Clinicaltrials.gov. Clinicaltrials.gov is the largest website listing of registered clinical research studies in the world. The study numbers and the clinical trial numbers are provided in order to make it easier for the reader to obtain further information. The book also contains an introduction to Stargardt Disease as well as analysis of the clinical trials.
Clinical Trials in Stargardt Disease Treatment is a valuable resource for ophthalmologists, optometrists, other physicians, and researchers.
Jeffrey N. Weiss, M.D., is the former Chief of Retinal Surgery at the Joslin Diabetes Center in Boston, Faculty of Harvard Medical School, and Visiting Scientist at the Massachusetts Institute of Technology.
Dr. Weiss is the author of more than 100 publications, including 20 books, holds more than 20 U.S. and foreign patents and has been a Reviewer for multiple scholarly journals. He has served as a Visiting Professor, performed surgery, and lectured both nationally and internationally. Dr. Weiss is also the founder of two companies, Ocular Research Associates Inc., and Micron Ophthalmic, Inc., which have manufactured and sold Dr. Weiss' inventions worldwide.
Dr. Weiss was the first to invent the equipment and develop the technique to safely perform retinal vessel cannulation. This surgery remains the only option for patients with severe stroke in the eye. He was also the first to report the use of hyperbaric oxygen treatment tosuccessfully treat dry age-related macular degeneration and longer standing central retinal artery occlusions.
Dr. Weiss performed the first retinal stem cell surgery in 2010, and is the Principal Investigator of The Stem Cell Ophthalmology Treatment Studies I/II, the largest retinal and optic nerve stem cell studies in the world, and The Neurologic Stem Cell Treatment Study. The studies are Institutional Review Board (IRB) approved, registered with NIH, and listed on ClinicalTrials.gov.
Part 1: Introduction.- Chapter 1. Introduction to Stargardt Disease.- Chapter 2. Tables.- Part 2: Recruiting Clinical Trials.- Chapter 3. United States.- Chapter 4. Spain.- Chapter 5. Switzerland.- Part 3: Enrolling by Invitation Clinical Trials.- Chapter 6. United States.- Part 4: Active, Not Recruiting.- Chapter 7. United States.- Chapter 8. Australia.- Part 5: Completed.- Chapter 9. United States.- Chapter 10. Brazil.- Chapter 11. China.- Chapter 12. Colombia.- Chapter 13. Europe.- Chapter 14. United Kingdom.- Chapter 15. No Location.- Part 6: Terminated.- Chapter 16. United States.- Chapter 17. China.- Chapter 18. Europe.- Chapter 19. Korea.- Chapter 20. United Kingdom.
| Erscheinungsdatum | 07.07.2024 |
|---|---|
| Zusatzinfo | XII, 236 p. |
| Verlagsort | Cham |
| Sprache | englisch |
| Maße | 155 x 235 mm |
| Themenwelt | Medizin / Pharmazie ► Medizinische Fachgebiete ► Augenheilkunde |
| Schlagworte | Clinical Trials in Ocular Therapy • Clinical Trials in Stargardt Disease Treatment • New Treatments in Stargardt Disease • Stargardt disease • Stargardt Disease Treatment • Stem Cells in Ocular Therapy |
| ISBN-10 | 3-031-58806-1 / 3031588061 |
| ISBN-13 | 978-3-031-58806-8 / 9783031588068 |
| Zustand | Neuware |
| Haben Sie eine Frage zum Produkt? |
aus dem Bereich
